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Atypical cancer pattern in patients with Parkinson’s disease
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Among 14 088 patients, with a primary diagnosis of Parkinson’s disease during the period 1977–98 identified from the National
Register of Patients, 1282 cancers were subsequently recorded in the Danish Cancer Registry, compared with 1464 expected, with a
standardised incidence ratio (SIR) of 0.88 (95% confidence interval (CI), 0.8–0.9). Significantly reduced risks were found for smoking-
related cancers, for example, cancers of the lung (SIR, 0.38), larynx (0.47) and urinary bladder (0.52), although moderate reductions in
risk were also seen for several nonsmoking-related cancers. In contrast, increased risks were seen for malignant melanoma (SIR, 1.95;
95% CI, 1.4–2.6), nonmelanocytic skin cancer (1.25; 1.1–1.4) and breast cancer (1.24; 1.0–1.5). The observed cancer pattern
supports the hypothesis that constituents of tobacco smoke inhibit or delay the development of Parkinson’s disease, but a low
smoking prevalence appears to be only part of the explanation for the decreased cancer incidence. The increased relative risks of
melanoma and nonmelanoma skin cancer are not likely to be artefactual, but further investigations of potential mechanisms are
warranted.
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Parkinson’s disease is a movement disorder of middle or late life,
characterised by an abnormal loss of pigmented neurons of
unknown cause and mechanism in the substantia nigra of the brain
stem. As early as in 1954, Doshay noted that ‘for reasons as yet
unclear, cancer is phenomenally rare in paralyses agitans’ (Doshay,
1954). Formal cohort studies of cancer incidence (Jansson and
Jankovic, 1985; Mller et al, 1995; Minami et al, 2000) and cancer
mortality (Ben-Shlomo and Marmot, 1995; Vanacore et al, 1999;
Minami et al, 2000) in patients with Parkinson’s disease
subsequently confirmed the overall pattern of a reduced risk.
The risk reduction has been related to the relatively consistent
observation that a high proportion of individuals who later
develop Parkinson’s disease are lifelong nonsmokers, as compared
with the general population (Hernan et al, 2002). However, a few
specific cancer types have been reported to occur in excess of
expected numbers, including cancers of the thyroid and the female
breast (Jansson and Jankovic, 1985; Mller et al, 1995; Minami et al,
2000) and malignant melanoma of the skin (Jansson and Jankovic,
1985; Mller et al, 1995). Treatment of Parkinson’s disease with
levo-dopa has been suggested as a causal factor in the latter
association, because levo-dopa serves as a substrate for the enzyme
tyrosine hydroxylase, which is involved in the production of
dopamine and melanin (Kincannon and Boutzale, 1999; Fiala et al,
2003).
Here, we report the results of an extension of a Danish cohort
study (Mller et al, 1995) of cancer in patients with Parkinson’s
disease.
METHODS
The study cohort was identified from the files of the Danish
National Hospital Register, which was instituted on 1 January 1977
and contains information on all nonpsychiatric hospital admis-
sions in Denmark (Andersen et al, 1999). Since 1 January 1994, it
has been supplemented by information on outpatient visits to
somatic disease departments. Each admission or outpatient visit
initiates a record flagged by the personal identification number of
the patient, a number which incorporates sex and date of birth and
which permits accurate linkage between nationwide registers.
The study covered 14 502 patients whose admission or out-
patient records for 1977–98 included a primary diagnostic code
for Parkinson’s disease (ICD-8 code 342 and ICD-10 code G20).
For patients who had been referred more than once to hospital or
outpatient clinic with a diagnosis of Parkinson’s disease, only the
first record was retained and provided the date of entry into the
study. Cohort members were linked to the Danish National
Mortality Files in order to verify vital status through 1999. A total
of 32 patients (0.2%) were excluded from the cohort because their
identification number indicated that they were citizens of the
Faroe Islands or Greenland. A further 369 (2.9%) were excluded
because they had died during their stay in hospital. We also chose
to exclude 13 patients (0.1%) who were discharged with a diagnosis
of Parkinson’s disease when they were under the age of 20. These
exclusions left a cohort of 14 088 patients for the analysis of
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subsequent cancer incidence, comprising 12 803 seen as in-patients
during the period 1977–98 and 1285 seen only as outpatients
during the period 1994–98 (Table 1). The age-specific and age-
standardised rates of Parkinson’s disease were calculated for men
and women separately per 100 000 individuals seen as in-patients
and out-patients. The age composition of the Danish population in
1987, totalling 5 127 070, was used as the standard.
Cohort members were linked to the files of the Danish Cancer
Registry in order to ascertain incident cases of cancer. The Cancer
Registry, which began reporting incidence data on a nationwide
scale in 1943, includes cases of nonmelanocytic skin cancer (basal
cell as well as squamous cell carcinoma), benign brain tumour and
bladder papilloma under cancers of the skin, brain and bladder,
respectively (Storm et al, 1997). The follow-up period for cancer
began on the date of first hospital discharge or outpatient visit with
a primary diagnosis of Parkinson’s disease and ended on the date
of death (n¼ 10 648) or on 31 December 1999 (n¼ 3440),
whichever occurred first (Table 1). The number of cancers
observed was compared with the numbers expected, which were
calculated by multiplying the number of person-years for cohort
members by the overall and site-specific incidence rates of cancer
for Danish men and women in 5-year age groups and calendar
periods of observation. Standardised incidence ratios (SIRs) for
cancer in patients with Parkinson’s disease, and 95% confidence
intervals (CIs) were calculated, assuming a Poisson distribution of
the observed cancers (Bailar and Ederer, 1964). Multiple primary
cancers in the same patient during follow-up were included in
observed as well as expected numbers.
To evaluate possible misclassification in the Danish Cancer
Registry of lentigo maligna or level I melanomas (which are
probably pre-invasive melanomas) as invasive melanomas, we
reviewed the original notification forms of all patients with
Parkinson’s disease who were registered with a malignant
melanoma (n¼ 44) and of an age- and sex-matched sample of
approximately four times as many individuals from the general
population registered in the Cancer Registry with malignant
melanoma (n¼ 168).
RESULTS
The 14 088 patients in this study had an average age at first
hospital admission or outpatient visit for Parkinson’s disease of
72.8 years and accrued 69 802 person-years of follow-up (average,
5.0 years; range, up to 23 years). Almost 13% of the patients were
followed up for at least 10 years. Table 2 gives the age-standardised
and age-specific incidence rates of a primary diagnosis of
Parkinson’s disease for inhabitants of Denmark during the
recruitment period 1977–98. The rates for the first years of
registration are somewhat inflated by inclusion of prevalent cases
of Parkinson’s disease, as some of the patients might have had the
disease for several years before the start of the National Hospital
Register in 1977. After 1994, an increasing number of cases were
diagnosed in outpatient clinics. During the 1990s, a steep increase
in the age-standardised incidence was seen among men, that is,
from 17 per 100 000 in 1989–91 to 28 per 100 000 in 1998, with a
modest increase among women over the same period (Table 2). In
the late 1970s, the male : female ratio for the disease was 1.2,
whereas in the late 1990s it was 1.9. Table 2 shows that the sex
difference in incidence grew with increasing age.
Overall, 1282 cancers were reported, whereas 1463.9 were
expected, with a SIR of 0.88 (95% CI, 0.8– 0.9), equivalent to a
significant cancer deficit of 12% (Table 3). Cancers at a few sites
Table 1 The distribution of patients with a diagnosis of Parkinson’s
disease during 1977–1998 by sex, year of birth, type of patient and vital
status on 31 December 1999 (end of follow-up)
Characteristic Men (%) Women (%) Both sexes (%)
All patients 7190 (100) 6898 (100) 14 088 (100)
Year of birth
o1900 412 (6) 466 (7) 878 (6)
1900–1919 4674 (65) 4723 (68) 9397 (67)
1920–1939 1901 (26) 1576 (23) 3477 (25)
1940–1959 196 (3) 128 (2) 324 (2)
X1960 7 (o1) 5 (o1) 12 (o1)
Patient type
Inpatient 6474 (90) 6329 (92) 12 803 (91)
Outpatienta 716 (10) 569 (8) 1285 (9)
Vital status
Alive 1602 (22) 1838 (27) 3440 (24)
Deceased 5588 (78) 5060 (73) 10 648 (76)
aOn the basis of outpatient visits only.
Table 2 Age-standardised and age-specific rates of Parkinson’s disease (PD) in Denmark per 100 000 men (n¼ 7190) and women (n¼ 6898)
Men Women
Characteristic Inpatient Outpatient All Inpatient Outpatient All Both sexes (all)
Perioda
1977–1979 23.1 23.1 18.5 18.5 20.4
1980–1982 21.3 21.3 16.7 16.7 18.5
1983–1985 19.3 19.3 14.1 14.1 16.2
1986–1988 17.5 17.5 11.5 11.5 13.8
1989–1991 17.0 17.0 12.4 12.4 14.2
1992–1994 16.7 4.8 18.3 10.4 2.6 11.3 14.0
1995–1997 16.8 8.9 25.7 10.2 5.3 15.3 19.5
1998 15.8 11.7 27.6 8.5 6.1 14.6 19.9
Age at first discharge (years)
20–34 0.1 0.0 0.1 0.1 0.0 0.1 0.1
35–49 1.0 0.2 1.2 0.9 0.1 1.0 1.1
50–64 10.7 1.5 12.2 8.5 0.9 9.4 10.8
65–79 68.4 6.8 75.2 53.5 4.1 57.6 65.4
X80 110.2 13.1 123.3 57.5 6.9 64.4 84.3
aPeriod of first inpatient registration (1977–1998), or if no inpatient registration first outpatient registration (1994–1998).
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occurred more frequently than in the general population, including
malignant melanoma (SIR, 1.95; 1.4– 2.6), nonmelanocytic skin
cancer (1.25; 1.1–1.4) and cancers of the breast (1.24; 1.0–1.5),
brain (1.32; 0.9–1.9) and at unspecified or secondary sites (1.21;
1.0–1.5). Excluding malignant melanoma and nonmelanocytic
skin cancer generated a 19% deficit (SIR, 0.81; 0.8– 0.9). The
overall decreased risk was mainly due to a markedly reduced risk
for smoking-related cancers (combined SIR, 0.58; 0.5– 0.6). In
particular, reductions were seen for cancers of the lung (SIR, 0.38),
larynx (0.47) and urinary bladder (0.52), which are the cancers
most strongly associated with tobacco smoking. Nevertheless,
lower rates of several other site-specific cancers presumably not
related to tobacco smoking were also seen, most notably cancers of
the prostate (0.74), colon (0.84) and rectum (0.89).
The risk for all cancers was significantly reduced for men (SIR,
0.79; 0.7– 0.9), but not for women (0.98; 0.9– 1.1) (Figure 1). The
risks for cancer at individual sites, however, were similar for men
and women, for example, SIRs of 0.33 and 0.65 for lung cancer,
0.50 and 0.59 for bladder cancer, 2.00 and 1.91 for malignant
melanoma and 1.23 and 1.27 for nonmelanocytic skin cancer,
respectively. Kidney cancer was the only exception, with SIRs for
men and women of 0.66 (0.4–1.1) and 1.19 (0.7–1.9), respectively,
on the basis of 14 and 19 observed cancers. The difference in the
sex-specific overall risk was mainly due to the fact that smoking
represents a smaller burden of cancer in women than in men, that
the excess risk for breast cancer has a comparatively larger impact
in women, and that a marked deficit was found among men for
prostate cancer.
In a further analysis by time since entry (Table 4), there was a
tendency for an increasing risk reduction with increasing length of
follow-up for cancer overall and for most site-specific cancers,
both smoking and nonsmoking related. The trend for breast cancer
in women, however, showed clearly increasing estimates with
increasing length of follow-up. The risk of malignant melanoma
was particularly high during the first 5 years of follow-up. The
excess risk for brain cancer seen initially might be at least partly
due to diagnostic misclassification, if early symptoms of brain
cancer were wrongly diagnosed as a sign of Parkinson’s disease, or
detection bias, if brain cancers were diagnosed during the clinical
work-up for Parkinson’s disease.
Malignant melanoma of the skin
We reviewed the Cancer Registry notification forms for 43 of 44
cohort members registered with a malignant melanoma (one
patient was notified on the basis of a death certificate only) and the
notification forms of a random sample of 168 individuals likewise
registered with a malignant melanoma. ‘Lentigo maligna’ or ‘level I
melanoma’ (regarded as pre-invasive) appeared on the notification
forms of three (7%) of the 43 cohort members and 16 (10%) of the
168 individuals in the random sample. The severity of the lesion
was not given for 27% of the cohort members and for 23% of the
sample, while invasiveness was clearly stated on the notification
forms of 66% of the cohort members and 67% of the sample.
DISCUSSION
In this population-based study of more than 14 000 patients with a
primary diagnosis of Parkinson’s disease, we observed a statisti-
cally significant overall 42% decrease in the risk for cancer at sites
related to tobacco smoking. The decrease was most pronounced
for men and for the smoking-related sites of lung, larynx and
urinary bladder, suggesting that the risk reduction was probably
due to a low prevalence of smoking. Large prospective studies have
uniformly shown that the incidence of Parkinson’s disease is about
60% lower among current smokers and 40% lower among past
smokers than among those who have never smoked, and that the
magnitude of the risk reduction diminishes with time since
quitting smoking (Hernan et al, 2002, 2001). Similarly reduced risk
estimates for Parkinson’s disease linked with cigarette smoking
were observed in large, well-conducted case–control studies
(Gorell et al, 1999; Checkoway et al, 2002). These findings led to
the hypothesis that constituents of tobacco smoke can reduce or
abolish the brain damage that triggers Parkinson’s disease. This
hypothesis of a true protective effect of tobacco smoke is further
supported by the recent observation that the risk for the disease in
both dizygotic and monozygotic twins is inversely associated with
the life-long dose of cigarette smoke, measured in pack-years
(Tanner et al, 2002).
Table 3 Standardised incidence ratios (SIR) for total and site-specific
cancers among 14 088 patients with a primary diagnosis of Parkinson’s
disease, 1977–1998
Site of cancer
(ICD-7)
No.
observed
No.
expected SIR 95% CI
All sites combined
(140–205)
1282 1463.9 0.88 0.8–0.9
Melanoma of
skin (190)
44 22.5 1.95 1.4–2.6
Other skin (191) 292 234.4 1.25 1.1–1.4
All sites except skin 990 1229.5 0.81 0.8–0.9
Breast 142 114.6 1.24 1.0–1.5
All sites except skin
and breast
804 1092.4 0.74 0.7–0.8
All smoking-related
sites
285 491.3 0.58 0.5–0.6
Lung (162.0–1) 66 174.8 0.38 0.3–0.5
Larynx (161) 5 10.7 0.47 0.2–1.1
Urinary bladder
(181)
50 95.3 0.52 0.4–0.7
Buccal cav.,
pharynx (140–
148)
15 24.6 0.61 0.3–1.0
Esophagus (150) 10 15.2 0.66 0.3–1.2
Myeloid
leukaemia (204,
partly)
10 14.4 0.69 0.3–1.3
Liver 10 14.4 0.70 0.3–1.3
Cervix uteri
(171)
10 13.1 0.76 0.4–1.4
Stomach (151) 39 47.0 0.83 0.6–1.1
Pancreas (157) 37 44.6 0.83 0.6–1.1
Kidney (180) 33 37.2 0.89 0.6–1.3
Other specified sites 422 521.3 0.81 0.7–0.9
Gallbladder 9 14.5 0.62 0.3–1.2
Ovary (175) 15 23.3 0.64 0.4–1.1
Multiple
myeloma (203)
12 17.3 0.69 0.4–1.2
Other
leukaemias (204,
partly)
16 22.4 0.71 0.4–1.2
Prostate (177) 90 121.9 0.74 0.6–0.9
Non-Hodgkin’s
lymphoma
(200, 202)
23 30.0 0.77 0.5–1.2
Colon (153) 120 142.2 0.84 0.7–1.0
Endometrium
(172)
23 26.6 0.87 0.6–1.3
Rectum (154) 63 70.5 0.89 0.7–1.1
Brain (193) 31 23.5 1.32 0.9–1.9
Remaining
specified sites
20 29.1 0.69 0.4–1.1
Secondary and
unspecified sites
97 80.1 1.21 1.0–1.5
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The descriptive epidemiology of Parkinson’s disease in Den-
mark appears at least partly to accord with a protective effect of
tobacco smoke: the smoking habits of Danish women have been
stable or perhaps increased slightly over the past three decades,
and their incidence of Parkinson’s disease is largely unchanged,
while the smoking habits of Danish men decreased over the same
period, which is consistent with their increased incidence of the
disease (Skuladottir et al, 2000; Juel, 2002). The observation that
the overall rate of Parkinson’s disease is higher in men than in
women, however, is not explained by changes in smoking habits in
the general population.
With the clear exception of cancers of the skin and breast, our
study also showed that the incidence of nonsmoking-related
cancers in the cohort was 19% lower than that of the general
population, although significant reductions were seen only for
cancers of the prostate and colon. We have no ready explanation
for the decreased risks for most nonsmoking-related cancers. A
negative surveillance bias might have arisen from the relatively
poor communication ability of the patients most seriously affected
by their movement disorder, as certain malignancies might have
been missed in such patients, leading to a reduced number of
notifications to the Cancer Registry. This is, however, unlikely to
explain the overall low incidence, as the risk reduction was seen
from the date of the first notification of Parkinson’s disease.
Moreover, the significant excesses of cancers of the breast and skin
speak against a general under-diagnosis of cancer in this patient
group. If the observed decreases in the risks for most nonsmoking-
related cancers are not due to bias, they suggest other aetiologic
hypotheses. If it is assumed that apoptosis in the substantia nigra
is a manifestation of the apoptotic potential of the patient in
general, the development of Parkinson’s disease might be
considered a marker for an individual’s ability to induce cell
death by apoptosis, that is, to provide protection against the effects
of mutagenic exposures, including to tobacco and other chemical
carcinogens.
The increased relative risk for skin cancer was so marked in our
study (about 25% for nonmelanocytic skin cancer, based on 292
observed cases, and two-fold for malignant melanoma, based on 44
cases) that it is unlikely to be completely explained by better
medical surveillance of these patients. Moreover, as a serious
cancer, it is likely at some time to be diagnosed and notified to the
Cancer Registry. Our review of the notifications of patients with
Parkinson’s disease and malignant melanoma did not confirm the
suspicion that pre-invasive cases of malignant melanoma are more
often reported to the Cancer Registry for patients with Parkinson’s
disease than for Danish residents in general. Solar radiation is the
main cause of both malignant melanoma and nonmelanocytic skin
cancer (International Agency for Research on Cancer, 1992). In a
study of avoidable cancers in the Nordic countries, it was
estimated that 85– 90% of all malignant melanomas diagnosed
are caused by solar radiation (Olsen et al, 1997), and similar
estimates for nonmelanocytic skin cancer have been published
(Harvard Center for Cancer Prevention, 1996). We have no reason
to believe that individuals who develop Parkinson’s disease also
belong to the subgroup of the population who has above-average
participation in outdoor activities, with ambient exposure to
sunlight and episodes of sunburn. The specific hypothesis of a
causal association between malignant melanoma (and possibly
other skin cancers) and treatment with levodopa is currently under
Table 4 Standardized incidence ratios (SIRs) for cancers at selected sites
among 14 088 patients with Parkinson’s disease by period of follow-up
Time since first hospitalisation (years)
o1 1–4 5–9 X10
Site of cancer
(ICD-7) SIR (n) SIR (n) SIR (n) SIR (n)
All sites combined
(140–205)
0.99 (260) 0.89* (630) 0.80* (273) 0.78* (119)
Malignant
melanoma (190)
2.35* (9) 2.18* (23) 1.66 (9) 1.11 (3)
Non-melanoma
skin (191)
1.10 (44) 1.29* (143) 1.34* (75) 1.10 (30)
Female breast
(170)
1.10 (20) 1.16 (62) 1.24 (36) 1.72* (24)
Lung (162.0–1) 0.42* (14) 0.39* (33) 0.23* (9) 0.59 (10)
Urinary bladder
(181)
0.67 (12) 0.60* (28) 0.32* (7) 0.32* (3)
Prostate (177) 1.12 (27) 0.61* (37) 0.80 (21) 0.46 (5)
Colon (153) 1.13 (28) 0.92 (63) 0.65* (22) 0.46* (7)
Rectum (154) 1.00 (13) 0.99 (34) 0.68 (11) 0.72 (5)
Brain (193) 1.46 (6) 1.62 (18) 0.90 (5) 0.75 (2)
Secondary and
unspecified sitesa
1.85* (15) 1.42 (32) 0.87 (10) 0.72 (4)
*Po0.05. aICD-7 codes 198 and 199.
Men
0.3 0.5 0.7 0.9 1.1 1.3 1.5 1.7 1.9 2.1 2.3 0.3 0.5 0.7 0.9 1.1 1.3 1.5 1.7 1.9 2.1 2.3
All sites combined
Breast
Malignant melanoma
Other skin
Brain
Corpus uteri
Cervix uteri
Ovary
Pancreas
Stomach
Liver, gall bladder
Rectum
Colon
Prostate
Non-Hodgkin's lymphoma
Multiple myeloma
Leukaemia
Kidney
Oesophagus
Urinary bladder
Buccal cavity
Lung
Women
Figure 1 Relative risks for cancers at all sites combined and for individual sites, in men and women with Parkinson’s disease in Denmark, 1977–98.
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debate (Fiala et al, 2003) and could not be evaluated in the present
study as we had no systematic information on the treatment
received by the patients over the years.
We have no explanation for our finding of a marginally
significant, 23% increase breast cancer, based on a total of 139
observed cases. An excess of incident cases of breast cancer was
also seen in a smaller Japanese study (Minami et al, 2000). In
contrast, a decreased mortality from breast cancer was seen in an
Italian study, based on 29 cases. We had no information on the
reproductive factors that are important potential confounders in
studies of female breast cancer, although these factors are unlikely
to be associated with Parkinson’s disease.
Patients with less severe disease were potentially missing
from our cohort, implying that the atypical cancer pattern
of patients with Parkinson’s disease is not fully representative
of that of all patients with the disease, although the inclusion
of outpatient diagnosed patients may have ameliorated this
potential shortcoming. Our results point to the need for
hypotheses to explain why patients with Parkinson’s disease are
protected from most cancers but at the same time are at increased
risk for melanoma and non-melanoma skin cancer, and perhaps
breast cancer.
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